Maltodextrin
Maltodextrin is an unknown pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
1377 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | 2 | 4 | 3 | 2 | 89 | 99 |
| Healthy volunteers/patients | — | — | — | 4 | 6 | 2 | 2 | 79 | 90 |
| Overweight | D050177 | — | E66.3 | 3 | 6 | 1 | 2 | 42 | 52 |
| Constipation | D003248 | — | K59.0 | 2 | 6 | 3 | 3 | 38 | 50 |
| Inflammation | D007249 | MP_0001845 | — | 3 | 2 | 4 | 1 | 38 | 48 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | 1 | 5 | 2 | 2 | 29 | 37 |
| Irritable bowel syndrome | D043183 | EFO_0000555 | K58 | 1 | 4 | 1 | 2 | 28 | 35 |
| Infections | D007239 | EFO_0000544 | — | — | 6 | 2 | 1 | 21 | 30 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 2 | 1 | — | 1 | 23 | 26 |
| Gastrointestinal microbiome | D000069196 | — | — | — | — | 1 | 1 | 23 | 25 |
Show 54 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sarcopenia | D055948 | EFO_1000653 | M62.84 | — | 3 | 3 | — | 38 | 43 |
| Syndrome | D013577 | — | — | 5 | 10 | 4 | — | 28 | 39 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | 2 | 3 | 1 | — | 25 | 29 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | 2 | 1 | — | 24 | 26 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | 4 | 1 | — | 20 | 24 |
| Gastrointestinal diseases | D005767 | — | — | — | — | 1 | — | 23 | 24 |
| Hypertension | D006973 | EFO_0000537 | I10 | 7 | 3 | 1 | — | 14 | 22 |
| Fatty liver | D005234 | EFO_0003934 | — | 1 | 4 | 1 | — | 17 | 21 |
| Communicable diseases | D003141 | — | — | — | 4 | 1 | — | 16 | 21 |
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | — | 2 | 1 | — | 13 | 15 |
Show 69 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Aging | D000375 | GO_0007568 | R41.81 | 4 | 1 | — | — | 19 | 24 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | 2 | — | — | 16 | 18 |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | 1 | 1 | — | — | 14 | 16 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | 1 | 2 | — | — | 12 | 15 |
| Fatigue | D005221 | — | R53.83 | — | 1 | — | — | 14 | 15 |
| Respiratory tract infections | D012141 | — | J06.9 | 1 | 3 | — | — | 10 | 14 |
| Digestive signs and symptoms | D012817 | — | — | 2 | 2 | — | — | 8 | 10 |
| Diet therapy | D004035 | — | — | — | 1 | — | — | 8 | 9 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 3 | — | — | 6 | 9 |
| Immunity | D007109 | — | — | 1 | 1 | — | — | 7 | 9 |
Show 49 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Metabolic diseases | D008659 | EFO_0000589 | E88.9 | 1 | — | — | — | 10 | 11 |
| Sleep initiation and maintenance disorders | D007319 | — | F51.01 | 1 | — | — | — | 10 | 11 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | 1 | — | — | — | 10 | 11 |
| Iron-deficiency anemia | D018798 | — | D50 | 1 | — | — | — | 9 | 10 |
| Oxidative stress | D018384 | EFO_1001905 | — | 1 | — | — | — | 9 | 10 |
| Microbiota | D064307 | — | — | 1 | — | — | — | 8 | 9 |
| Body composition | D001823 | — | — | 1 | — | — | — | 5 | 6 |
| Food hypersensitivity | D005512 | EFO_1001890 | — | 1 | — | — | — | 4 | 5 |
| Protein deficiency | D011488 | — | — | 1 | — | — | — | 3 | 4 |
| Metabolism | D008660 | GO_0008152 | — | 1 | — | — | — | 3 | 4 |
Show 27 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Exercise | D015444 | EFO_0000483 | — | — | — | — | — | 14 | 14 |
| Cognitive dysfunction | D060825 | — | G31.84 | — | — | — | — | 14 | 14 |
| Affect | D000339 | — | — | — | — | — | — | 14 | 14 |
| Healthy diet | D000072001 | — | — | — | — | — | — | 10 | 10 |
| Sleep | D012890 | GO_0030431 | — | — | — | — | — | 10 | 10 |
| Hyperglycemia | D006943 | — | R73.9 | — | — | — | — | 9 | 9 |
| Muscular atrophy | D009133 | — | — | — | — | — | — | 8 | 8 |
| Digestive system diseases | D004066 | EFO_0000405 | K92.9 | — | — | — | — | 8 | 8 |
| Chronic renal insufficiency | D051436 | — | N18 | — | — | — | — | 7 | 7 |
| Sleep wake disorders | D012893 | — | G47 | — | — | — | — | 7 | 7 |
Show 313 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Maltodextrin |
| INN | _ |
| Description | Maltodextrin is a name shared by two different families of chemicals. Both families are glucose polymers (called dextrose or dextrins), but have little chemical or nutritional similarity.
|
| Classification | Unknown |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | >5BJZ:C,D|Synthetic antibody, Fab fragment, Heavy Chain
EISEVQLVESGGGLVQPGGSLRLSCAASGFNLSSSSIHWVRQAPGKGLEWVASIYSYYGSTSYADSVKGRFTISADTSKN
TAYLQMNSLRAEDTAVYYCAREYHSYWSYSWWPRVGLDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT
>5BJZ:L,H|Synthetic antibody, Fab fragment, Light Chain
SDIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQ
PEDFATYYCQQASLTALLTFGQGTKVEIKRTVAAPSVFIFPPSDSQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGN
SQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
Identifiers
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
19 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use